FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date ...

FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set ...

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) ...

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

The FDA has accepted for Priority Review the BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis.

Aims Juvenile onset Recurrent Respiratory Papillomatosis (JoRRP) is a rare chronic disease caused by human papillomavirus (HPV) types 6 and 11. Children with RRP require multiple surgical ...

U.S. health officials have expanded the recommended age range for people receiving the HPV vaccine to protect against several types of cancer to people in their mid-40s. MSK physicians offers advice ...

Infection with HPV 6 or HPV 11 causes RRP, a lifelong neoplastic disease of the upper and lower respiratory tracts that can be fatal. According to Precigen, some 27,000 U.S. adults have RRP based ...

NEW YORK – The US Food and Drug Administration has accepted Precigen's biologics license application for PRGN-2012 (zopapogene imadenovec), a gene therapy that it is developing for recurrent ...

Human papillomavirus (HPV) tests in the province will replace Pap tests, also known as Pap smears or cervical cytology, on March 3, following similar moves in British Columbia and Prince Edward ...